Clinical Trial Detail

NCT ID NCT02389764
Title Nintedanib For HER2-negative Metastatic Inflammatory Breast Cancer (MIBC)
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements yes
Sponsors M.D. Anderson Cancer Center
Indications

Her2-receptor negative breast cancer

Therapies

Nintedanib

Age Groups: adult

Additional content available in CKB BOOST